Clearpoint Neuro Correlations
CLPT Stock | USD 11.09 0.13 1.19% |
The current 90-days correlation between Clearpoint Neuro and Telesis Bio is -0.06 (i.e., Good diversification). The correlation of Clearpoint Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Clearpoint Neuro Correlation With Market
Weak diversification
The correlation between Clearpoint Neuro and DJI is 0.35 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Clearpoint Neuro and DJI in the same portfolio, assuming nothing else is changed.
Clearpoint |
Moving against Clearpoint Stock
0.46 | DOCS | Doximity | PairCorr |
0.4 | FOXO | FOXO Technologies | PairCorr |
0.41 | CRVL | CorVel Corp Normal Trading | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Clearpoint Stock performing well and Clearpoint Neuro Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Clearpoint Neuro's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
TBIO | 10.30 | 1.47 | 0.09 | (0.85) | 12.47 | 18.58 | 139.53 | |||
RCEL | 2.36 | 0.34 | 0.15 | 0.27 | 2.41 | 5.77 | 14.73 | |||
SGHT | 3.06 | (1.05) | 0.00 | (0.22) | 0.00 | 6.96 | 18.22 | |||
TMCI | 3.16 | (0.01) | 0.11 | 0.10 | 2.76 | 6.08 | 38.73 | |||
NPCE | 3.44 | 0.17 | 0.09 | 0.17 | 3.21 | 9.73 | 35.38 | |||
INGN | 1.92 | (0.54) | 0.00 | (0.36) | 0.00 | 2.66 | 22.50 | |||
SRDX | 0.48 | (0.07) | 0.00 | (0.13) | 0.00 | 1.26 | 3.22 | |||
LUNG | 3.25 | (0.30) | 0.00 | (0.04) | 0.00 | 9.00 | 20.52 | |||
APYX | 3.29 | 0.24 | 0.06 | 0.38 | 3.26 | 9.38 | 32.02 | |||
OSA | 104.70 | 50.88 | 1.97 | 3.14 | 13.81 | 51.22 | 168.97 |
Clearpoint Neuro Corporate Management
Mazin Sabra | Chief Officer | Profile | |
Danilo DAlessandro | Chief Officer | Profile | |
Ellisa JD | General Secretary | Profile | |
Ellisa Cholapranee | General Secretary | Profile | |
Jeremy Stigall | Executive Delivery | Profile | |
Jacqueline Keller | Vice Marketing | Profile |